Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Johnson
Dale N Gerding

Showing results (101-110 of 283) with videos related to

Pageof 29
Sort By:
Infection Control and Hospital Epidemiology|March 19, 2015
Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort studyLarry K Kociolek, Sameer J Patel, Stanford T Shulman, et al.
Microbes and Infection|February 3, 2018
Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106Larry K Kociolek, Dale N Gerding, David W Hecht, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Concomitant Medical Conditions and Therapies Preclude Accurate Classification of Children With Severe or Severe Complicated Clostridium difficile InfectionLarry K Kociolek, Sameer J Patel, Stanford T Shulman, et al.
BMC Infectious Diseases|March 13, 2022
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trialRobert Orenstein, Erik R Dubberke, Sahil Khanna, et al.
Antimicrobial Agents and Chemotherapy|August 2, 2012
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjectsStephen A Villano, Michael Seiberling, Walter Tatarowicz, et al.
Nature|March 3, 2009
Toxin B is essential for virulence of Clostridium difficileDena Lyras, Jennifer R O'Connor, Pauline M Howarth, et al.
Frontiers in Microbiology|January 7, 2022
Host Immune Responses to <i>Clostridioides difficile</i>: Toxins and BeyondBritt Nibbering, Dale N Gerding, Ed J Kuijper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 19, 2005
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genesM Catherine McEllistrem, Robert J Carman, Dale N Gerding, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2018
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile InfectionErik R Dubberke, Christine H Lee, Robert Orenstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 26, 2014
Lack of evidence for an unmet need to treat Clostridium difficile infection in infants aged <2 years: expert recommendations on how to address this issueSaul N Faust, Mark H Wilcox, Aleksandra Banaszkiewicz, et al.
Pageof 29

Showing results (101-110 of 283) with videos related to

Sort By:
Pageof 29
Infection Control and Hospital Epidemiology|March 19, 2015
Molecular epidemiology of Clostridium difficile infections in children: a retrospective cohort studyLarry K Kociolek, Sameer J Patel, Stanford T Shulman, et al.
Microbes and Infection|February 3, 2018
Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106Larry K Kociolek, Dale N Gerding, David W Hecht, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Concomitant Medical Conditions and Therapies Preclude Accurate Classification of Children With Severe or Severe Complicated Clostridium difficile InfectionLarry K Kociolek, Sameer J Patel, Stanford T Shulman, et al.
BMC Infectious Diseases|March 13, 2022
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trialRobert Orenstein, Erik R Dubberke, Sahil Khanna, et al.
Antimicrobial Agents and Chemotherapy|August 2, 2012
Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjectsStephen A Villano, Michael Seiberling, Walter Tatarowicz, et al.
Nature|March 3, 2009
Toxin B is essential for virulence of Clostridium difficileDena Lyras, Jennifer R O'Connor, Pauline M Howarth, et al.
Frontiers in Microbiology|January 7, 2022
Host Immune Responses to <i>Clostridioides difficile</i>: Toxins and BeyondBritt Nibbering, Dale N Gerding, Ed J Kuijper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 19, 2005
A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genesM Catherine McEllistrem, Robert J Carman, Dale N Gerding, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2018
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile InfectionErik R Dubberke, Christine H Lee, Robert Orenstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 26, 2014
Lack of evidence for an unmet need to treat Clostridium difficile infection in infants aged <2 years: expert recommendations on how to address this issueSaul N Faust, Mark H Wilcox, Aleksandra Banaszkiewicz, et al.
Pageof 29